Predicting heart failure using the plasma proteome

ABSTRACT

To determine whether the plasma proteome adds value to established predictors in heart failure (HF) with reduced ejection fraction (HFrEF). We sought to derive and validate a plasma proteomic risk score (PRS) for survival in patients with HFrEF (HFrEF-PRS).

Until recently, proteomics had not been as thoroughly explored partly due to comparatively low-throughput. However, emerging proteomic technologies have recently matured and newer high-throughput techniques now allow larger scale proteomic characterization. One of these newer technological innovations, enhanced aptamer-based assays, has enabled a massively expanded candidate approach that borders on true proteomics in scale; thousands of protein-derived factors can be efficiently assayed simultaneously in a small biologic sample. In this webinar, you will explore this new large-scale protein array using an established HF patient registry to understand how the plasma proteome could meaningfully predict the risk of death or HF worsening and add to best conventional risk stratification, including clinical score and natriuretic peptides. By using the circulating proteome to improve risk prediction, it could add a new tool to help manage patients with HF and contribute to discovery of novel HF markers and pathways.

david-headshot

David E. Lanfear, MD, MS, FAHA, FACC, FHFSA

Section Head, Advanced Heart Failure and Transplant Cardiology Co-Director, Center for Individualized and Genomic Medicine Research Professor of Medicine, WSU-SoM Henry Ford Hospital

DAVID E. LANFEAR, MD, MS, Research Professor of Medicine, is Head of the Advanced Heart Failure and Transplant Cardiology at Henry Ford Hospital in Detroit, and Co-Director of the Center for Individualized and Genomic Medicine Research (CIGMA). Dr. Lanfear is a practicing transplant cardiologist, a clinician scientist with a track record of NIH-funded projects on precision medicine and genomics as well as an active trialist with experience in single and multicenter clinical trials. He has more than 140 published manuscripts, reaching high-impact journals including JAMA and NEJM. He is Associate Editor at Circulation: Heart Failure and is on the Editorial Boards of JCF, Heart Failure Reviews, JACC:Cardio-oncology, JACC: Basic to Translational Science.

Share with colleagues

More webinars

WebinarUtilizing proteomic strategies to uncover novel biomarkers and mechanisms in heart failure 

Plasma proteomics is a powerful approach for discovering novel protein biomarkers of drug toxicity in various disease contexts. One such biomarker in cardiovascular disease is apolipoprotein M (ApoM), which plays a crucial role in lipid metabolism and transport and is known to have both anti-inflammatory and cardioprotective effects in the body. Studying ApoM using proteomics requires various approaches to understand its expression, modifications, interactions, and functions in the proteome.

Learn more

WebinarUsing plasma proteomics to understand Alzheimer’s and other brain diseases

Dr. Walker discusses how he integrates proteomic, genetic, brain imaging and cerebral spinal fluid biomarkers from initially cognitively normal individuals who later develop dementia, in order to discover novel blood-based biomarkers and mechanistically relevant proteins for therapeutic target prioritization.

Learn more

WebinarProteomics for precision neuroscience: The power of protein analysis

This webcast highlights how academic, industry and government researchers are directly measuring protein abundance and function via multiplex proteomics to build more detailed characterizations of the biological systems underlying neurodegenerative diseases.

Learn more

Explore webinars in our interactive viewer